OKTA vs CRWD: side-by-side analysis
Cross-read of OKTA (Okta Inc.) versus CRWD (CrowdStrike Holdings Inc.): OKTA looks meaningfully overvalued at $83.9 versus a fair-value midpoint of $39.3, while CRWD appears in our peer table. Our current rating for OKTA is Sell.
Where OKTA and CRWD sit on fair value
OKTA's composite fair-value range is $26.9–$51.8 (midpoint $39.3), versus a current price of $83.9. CRWD is one of OKTA's closest sector neighbours and shows up directly in the peer table inside our full report. The cross-read is editorial: same archetype expectations, same discount-rate philosophy, different operating model.
Both names are evaluated under the same six-factor decision overlay (customer value, unit economics, TAM, moat durability, risk profile, valuation) so comparing them is apples-to-apples rather than headline-multiple-to-headline-multiple. The rating differential between OKTA and CRWD is driven by where each lands across those six axes, not by who looks "cheaper" on a single screen.
Where they actually differ
OKTA is classified as a mature compounder stock; the archetype dictates our deceleration curve, terminal multiple, and probability weights. CRWD, depending on its own archetype, will have its own calibration — and that is precisely why simple peer multiples can mislead. A 19.8× forward P/E with a PEG of 2.48 is not the same on OKTA as it is on CRWD unless they share the same growth profile, capital intensity, and moat half-life.
OKTA's moat assessment is 6.5/10, and the full moat section in the report covers the source (network effects, switching costs, intangibles, scale, etc.) plus the timeline of any threats. The cross-read against CRWD should focus on which company's economic profit (ROIC minus WACC) is wider AND more durable — that is the variable that dominates long-run total return between two same-sector names.
Which one wins on each dimension
Valuation: OKTA looks meaningfully overvalued versus our fair-value midpoint. The full report's peer table compares OKTA and CRWD directly on P/E, PEG, EV/EBITDA, ROE, and operating margin. Risk: the bear case for OKTA is bound by the kill-scenarios list in Section 2; the equivalent for CRWD would need its own report. We do not co-rate two companies on a single page.
Capital allocation and growth runway typically separate same-sector pairs more than the headline numbers suggest. The full report's capital-allocation paragraph and TAM analysis are the lenses we recommend before deciding whether OKTA or CRWD is the better expression of the same theme.
Bottom line — OKTA or CRWD?
Our rating for OKTA is Sell with a 84/100 confidence score; the rating already accounts for the relative-value information embedded in the peer table that includes CRWD. The cross-read is most useful when the two companies are real substitutes in a portfolio (same factor exposure, same end markets, same archetype) — otherwise the comparison is theatre.
For the full evidence on OKTA, including the explicit peer multiples versus CRWD and the rest of the comp set, see the canonical report at /stocks/okta/analysis. For CRWD's standalone report, see /stocks/crwd/analysis.
Frequently asked questions
OKTA vs CRWD: which is cheaper today?
OKTA looks meaningfully overvalued at $83.9 versus a fair-value midpoint of $39.3 (range $26.9–$51.8). The peer table inside the full report compares OKTA and CRWD directly on P/E, PEG, EV/EBITDA, ROE, and operating margin.
Is OKTA a better buy than CRWD?
Our current rating for OKTA is Sell; we do not co-rate CRWD on this page — see CRWD's own report. The cross-read is most useful for relative positioning, not for choosing one over the other in isolation.
What archetype is OKTA?
Okta Inc. is classified as a mature compounder stock, which determines our deceleration curve, terminal multiple, and probability weights. CRWD's own archetype is in its own report.
What is OKTA's moat score versus CRWD?
OKTA's moat score is 6.5/10. The full moat section covers source, durability, and threat timeline; CRWD's moat assessment is in its own standalone report.
Research for educational purposes. Not personalised investment advice. See the full OKTA report for the canonical evidence.